Satoshi Mamori1, Tadashi Asakura, Kiyoshi Ohkawa, Hisao Tajiri. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan. mamori@jikei.ac.jp
Abstract
AIM: To investigate the expression of survivin during the early stages of hepatocellular carcinoma (HCC). METHODS: Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared. In addition, to determine the survivin expression in response to anti-cancer drugs in early stage HCC, the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions. RESULTS: Survivin proteins were expressed in 64.7% of cells in early HCC specimens. A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens (low-rate group vs high-rate group) was observed. The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs. CONCLUSION: This study suggests that survivin could be used as a therapeutic target in early HCC.
AIM: To investigate the expression of survivin during the early stages of hepatocellular carcinoma (HCC). METHODS: Immunohistochemical expression of survivin in liver tumor and non-tumor tissue specimens taken from 17 patients was compared. In addition, to determine the survivin expression in response to anti-cancer drugs in early stage HCC, the survivin expression was determined after the treatment of the HCC cells with anti-cancer drugs under hypoxic culture conditions. RESULTS: Survivin proteins were expressed in 64.7% of cells in early HCC specimens. A correlation between the survivin expression rate in the peritumoral hepatocytes and the rate of expression in the HCC specimens (low-rate group vs high-rate group) was observed. The survivin protein concentration in HCC cells was increased by the combination of hypoxia and anti-cancer drugs. CONCLUSION: This study suggests that survivin could be used as a therapeutic target in early HCC.
Authors: T Ito; K Shiraki; K Sugimoto; T Yamanaka; K Fujikawa; M Ito; K Takase; M Moriyama; H Kawano; M Hayashida; T Nakano; A Suzuki Journal: Hepatology Date: 2000-05 Impact factor: 17.425
Authors: Elena Dudich; Lidia Semenkova; Igor Dudich; Alexander Denesyuk; Edward Tatulov; Timo Korpela Journal: FEBS J Date: 2006-07-26 Impact factor: 5.542
Authors: Robert Martin; Javier Irurzun; Jordi Munchart; Igor Trofimov; Alexander Scupchenko; Cliff Tatum; Govindarajan Narayanan Journal: Korean J Hepatol Date: 2011-03